AGGREGATION
Cellular protein damage control: interactomic analyses of MOAG-4 in C. elegans
| Coordinatore | ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 175˙974 € |
| EC contributo | 175˙974 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2012-IEF |
| Funding Scheme | MC-IEF |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-04-01 - 2015-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | coordinator | 175˙974.60 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Several age-related neurodegenerative disorders, such as Alzheimer’s, Parkinson’s and Huntington’s diseases, are characterized by the formation of pathogenic proteins aggregates in the brain. Although some regulators have been identified, how aggregates form during aging is poorly understood. Recently, a modifier of aggregation, MOAG-4, was identified as a positive regulator of aggregation in C. elegans models for neurodegenerative diseases. The role of MOAG-4 is evolutionarily conserved in the human orthologs SERF1A and SERF2. MOAG-4/SERF appears to regulate age-related proteotoxicity through a previously unexplored pathway. Therefore, how this regulator works and in which pathway it acts needs to be established. In this proposal I focus on identifying proteins that physically interact and cooperate with MOAG-4 to drive protein aggregation. To this end, I will express in worms that lack MOAG-4 a tagged version of MOAG-4 to co-purify MOAG-4 interacting proteins. I will use different proteomic approaches to identify putative substrates and proteins that may form functional complexes with MOAG-4. These interactions will be confirmed in vitro and in vivo. In addition, I will study the proteotoxicity phenotype in mutant worms that are impaired in the expression of these proteins. I will also analyze the protein aggregation process by monitoring aggregate formation in a test tube with purified proteins. The results of this project will reveal the mechanism by which MOAG-4 acts, and this will contribute to our understanding of how cells cope with toxic, aggregation-prone proteins during aging. Furthermore, new options will be opened for the development of therapeutic strategies to treat human neurodegenerative diseases.'